.
The development and validation of surrogate outcomes requires two steps: identification of an association between the surrogate outcome and a relevant clinical outcome; and confirmation that the effect of treatment intervention on the proposed surrogate accurately predicts the treatment effect in a clinical trial setting. It has been argued that for patients with liver disease, the interval between treatment and clinical outcomes -such as liver failure or the development of hepatocellular carcinoma (HCC) -is too long, and surrogate end points must be used instead 2 
Perhaps the best-known surrogate in hepatology is the sustained virologic response (SVR) in the treatment of HCV infection. Seemingly straightforward (as SVR indicates cure of HCV infection), even this outcome measure has been criticized because of a lack of validation within a randomized controlled trial 3 . This criticism has recently prompted a debate regarding the effectiveness of direct-acting antiviral (DAA) agents for the treatment of HCV, which also highlighted issues surrounding the use of surrogate end points in clinical trials for patients with other liver diseases. These issues include difficulties in defining the magnitude of clinical benefits with treatment, determining the effect of confounding variables in uncontrolled studies of antiviral treatments and the effect of competing causes of mortality in the extended follow-up. This final issue is of paramount importance in trials of DAA agents in which a large proportion of subsequent liver disease mortality is driven by alternative causes of liver disease, notably alcohol 4 , and also in trials of therapeutics for patients with NAFLD in which there is ongoing risk of mortality due to coronary heart disease and non-liver cancer, even if liver disease is halted.
In early-phase drug development for NAFLD, clinical studies have often focused on improvements in aspects of the NAFLD activity score (NAS) 5 . This score aims to quantify disease activity, and an improvement in the NAS has been seen as a key signal in the progression of treatments to phase III clinical trials (TABLE 1) . Although it is biologically plausible that the degree of liver injury defined by the presence and severity of NASH (and assessed using the NAS) is associated with fibrosis progression, epidemiological evidence supports the severity of fibrosis as being the principal driver of clinical events 6 . Importantly, there are no data that suggest that an improvement in NAS following treatment predicts improvements in clinical outcomes for patients.
More recently, there has been a move to assessing improvements in liver fibrosis in relatively short-duration (compared with the natural history of liver disease) studies that range from 24 to 48 weeks 7, 8 . Evaluating changes in fibrosis seems a more direct surrogate of likely clinical benefit as it is liver fibrosis that is the greatest risk factor for liver-related mortality 6 . The reliability of assessing changes in liver fibrosis over short periods remains to be proven in the context of NAFLD, but several phase III studies (TABLE 1) are now using an abbreviated time frame to expedite reporting.
There is a perception that pharmaco logical treatments are urgently required for patients with NAFLD or NASH. Consequently, there is agreement with the FDA that treatments developed for NASH might receive conditional approval if they meet early end points that assess resolution of NASH using NAS, or if they show improvements in liver fibrosis 2 . To gain final regulatory approval, treatments for NASH must show clinically relevant benefits. Liver-related events (for example, hepatic decompensation and/or the development of HCC) will be most frequent in patients with cirrhosis at baseline; however, only one of the ongoing phase III studies includes this patient popu lation (TABLE 1) . The selected end point in the remaining ongoing phase III studies is a composite of overall mortality, the development of cirrhosis and liver-related events. Of the three factors comprising this composite end point, the development of cirrhosis is probably the most frequent, as overall mortality will likely be low in a highly selected trial population, and liver-related The devotion to surrogate outcomes in drug development for liver disease
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Surrogate end points are often used in clinical trials where the time to clinical outcomes is long. In patients with liver disease, these surrogate outcomes are rarely validated. Without validation, treatment effects reported in trials might not directly translate to patient benefit after licensing.
events will follow the diagnosis of cirrhosis in the trial setting. For this reason, cirrhosis is itself still a surrogate end point. Critically, patients with NAFLD and NASH are at risk of mortality from other causes. Although individuals with advanced fibrosis and cirrhosis carry the greatest risk of complications of liver disease, liverrelated death is still less frequent than death from coronary heart disease and non-hepatic malignancy 6 . The devotion to surrogate outcomes has four main predictable adverse outcomes in drug development in NAFLD. First, the reliance on NAS, a non-validated surro gate outcome, might have led to the advancement of therapeutics to late-stage clinical trials that have no effect on the clinical outcomes of patients with NASH. These development false-positives are costly to industry and to patients enrolled in phase III clinical trials that require risky repeated interventions, including liver biopsy. Second, the use of this surrogate might also have led drug developers to discard drugs that could have been useful if a more appropriate outcome measure had been used in clinical trials. Third, if a drug in phase III trials does reach the composite clinical end point and a benefit from treatment is identified largely through a reduction in the incidence of cirrhosis, inevitably the real clinical benefit of treatments for NAFLD will be less than those predicted as a consequence of the competing mortality risk. Finally, selection of an end point that includes progression to cirrho sis denies the possibility of treatment to those with cirrhosis, who are in greatest need of treatment 9 . It is imperative that hepatology learns from the lessons of surrogate end point use in drug development for HCV. Surrogate outcome measures in drug development in NAFLD need to be validated, and the role of the development of cirrhosis as a surrogate measure needs to be evaluated. It might be that the ongoing phase III trials will begin to address validation of these surrogates, and extended follow-up studies of the trial populations should be mandated to maximize data that are collected.
In many ways, trials of therapeutics in NAFLD are more analogous to primary prevention studies in cardiovascular disease than they are to antiviral agents for hepatitis infections. As the estimated population prevalence of NAFLD resembles that of coronary heart disease 10 , it should be possible to undertake large-scale clinical trials of patients at high-risk of liver-related events that do not rely on improvements in liver histology or the development of cirrhosis as the primary outcomes, but rather identify the benefits of treatment relevant for the patient, such as prevention of hepatic decompensation, HCC and improvement in survival. This approach was required for the licensing of treatments for primary prevention of cardiovascular disease and so should be the standard for assessing proposed treatments for NAFLD and NASH. Trial designed to identify possible efficacy of selonsertib, directionality of effects only described using 95% confidence intervals. § Composite includes all-cause mortality, progression to cirrhosis and liver-related morbidity.
